The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc strengthens management team for future growth
Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac® registered on 16 European markets, today announces that the company is strengthening its management team through the recruitment of Lars Stubberud as Chief Technology Officer...International Awareness Initiative Against Strangles
Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, highlights the annual initiative Strangles Awareness Week – an international awareness campaign aimed at reducing the spread of strangles within the equine industry. In Sweden, the campaign...Intervacc brings together leading US and European experts to jointly tackle strangles
Today, Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, together with Dechra Pharmaceuticals PLC, is hosting a European Key Opinion Leader (KOL) meeting focused on advancing best practice in the prevention and control of strangles. The...Unprecedented decision opens the way for the launch of Strangvac in Iceland
Intervacc AB (publ) announces that Strangvac®, the company’s innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed...Nyhetstjänster
